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Purpose: To develop new sensitive, accurate, rapid and reproducible high performance liquid 
chromatography (HPLC) method to determine metronidazole levels in human plasma and to apply the 
method in a bioequivalence study. 
Methods: Metronidazole was extracted from human plasma through one step of protein precipitation by 
methanol using carbamazepine as internal standard (IS).  After centrifugation of the plasma sample, the 
supernatant layer was separated and injected into HPLC system using Eclipse XDB-phenyl column. The 
mobile phase consisted of phosphate buffer (pH 4.5): acetonitrile (95:5, v/v). The UV detector was set at 
320 nm. The bioavailability of the test metronidazole product (Brand A) was compared to a commercial 
metronidazole brand as reference product in 24 healthy volunteers who received a single dose 
equivalent to 500 mg of the test and reference products in a randomized balanced two-way cross-over 
design separated by two-week wash-out period.  
Results: Mean standard calibration curves of metronidazole over the concentration range of 0.05 – 30 
μg/ml were linear. No significant differences were found based on analysis of variance of the 
pharmacokinetics parameters required for the assessment of bioequivalence of test and reference 
formulations. The mean value and 90 %CI of test/reference ratios for the derived parameters were: 
Cmax, 9.64 vs. 8.38 (0.93 – 1.10), AUC0-24, 124.6 vs.122.3 μg.h/mL (0.973 – 1.051) and AUC0-∞, 140.9 
vs. 128.4 h/mL (1.15 – 1.23). 
Conclusion: The test metronidazole product was bioequivalent to the reference. The method is suitable 
for bioequivalence and pharmacokinetic studies in humans with a low limit of quantification of 0.05 
µg/ml.  
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INTRODUCTION 
 
Metronidazole is a prototype of the 
nitroimidazole class of antimicrobials, it has 
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been evaluated in the treatment of diverse 
anaerobic and gastrointestinal tract 
infections. Moreovere, metronidazole has 
often been studied for antibacterial activity 
against gram-negative aerobes and some 
gram-positive bacteria, including Bacteriodes 
fragilis that produces β-lactamases [1]. In 
healthy humans, metronidazole is absorbed 
rapidly and completely from the 
gastrointestinal tract and is metabolized in 
the liver by an oxidative pathway [2]. Liver is 
the main site of metabolism by side chain 
oxidation and glucuronide conjugation. A 
major portion of the dose of the drug is 
excreted in urine, largely as metabolites [3]. 
Metronidazole is one of the most widely used 
antibacterial compounds in the treatment of 
some types of periodontal disease such as 
aggressive periodontitis. Several methods 
have been reported for the measurement of 
metronidazole in biological fluids using mass-
spectrometry [4-6] or high performance liquid 
chromatography [7-10].  
 
The purpose of this study was to develop a 
rapid, low-cost method for extraction of 
metronidazole from plasma and apply it to a 
simple, accurate and sensitive chromato-
graphic determination of metronidazole 
bioavaialbility of generic and reference 




 Chemicals  
 
Sodium acetate (ADWIC, Egypt), glacial 
acetic acid, phosphoric acid, acetonitrile and 
methanol were obtained  from Lab-Scan, 
Ireland. These reagents were of analytical 
grade except acetonitrile which was of HPLC 
grade. Metronidazole and the internal 
standard (carbamazepine)  were obtained 
from Sigma (UK), The test product was 
metronidazole 125 mg/5 ml suspension 
(Brand A) while the reference product was 





A stock solution of metronidazole (1 mg/ml) 
and solution of carbamazepine as internal 
standard (200 µg/ml) were prepared in 
acetonitrile. Serial dilutions of the 
metronidazole standards (0.05 - 30 µg/ml) 
were prepared in acetonitrile as well as 
spiked in plasma. All the solutions were 
stored at 4 °C. Metronidazole  extraction 
involved protein precepitation by methanol. 
Methanol (500 µl) was added to a glass tube 
containing 200 µl of plasma sample and 25 µl 
of internal standard (I.S.). After mixing for 10 
s on a vortex mixer and centrifugation for 10 
min at 3500 rpm at 4 °C, 50 µl of the 
supernatant was injected directly into the 
HPLC instrument.  
 
 Chromatographic system 
 
The high pressure liquid chromatography 
(HPLC) apparatus used comprised of Waters 
pump controlled by Waters 610 controller, 
Waters 717 autosampler injector and Waters 
486 UV detector. Separation was performed 
using an analytical  Eclipse XDB-phenyl  (250 
x 4.6 mm), 5 µm particle size column 
(Agilent). For data acquisition and integration, 
Waters millennium software operated by 
Pentium III (450 MHz) processor (Compaq, 
UK) was used. 
 
The mobile phase consisted of 0.05M sodium 
acetate: acetonitrile: glacial acetic acid  
(75:25:1, v/v/v) with the pH adjusted to 4.0 




Specificity and selectivity 
 
The HPLC assay validation was carried out 
according to guidelines recommended by 
United States Food and Drug Administration 
(2001) [11]. The specificity and selectivity of 
the assay were investigated by comparing 
the retention times of metronidazole detected 
in the assay of drug-free plasma with those 
from injection of drug extracted from spiked 
plasma. 
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Limit of detection 
 
Calibration curves were constructed using 
series of standard metronidazole  in the 
range of 0.05- 30 μg/ml. The lower limit of 
detection was defined as the concentration at 
which the signal is  to-noise ratio was more 
than 3 times in response (peak area). 
Similarly, the lower limit of quantification was 
defined as the concentration at which the 
signal-to-noise ratio was not less than 5 
times in response (peak area). Both 
parameters were calculated using the 
calibration curve containing the least 




Extraction recovery was assessed by 
comparing the response for the same 
concentration of metronidazole dissolved in 
acetonitrile and injected directly to HPLC with 
those injected after extraction from spiked 
plasma using the extraction method indicated 
above. 
 
Accuracy, percision and linearity 
 
Intra-day precision and accuracy were 
assessed by analyzing six replicates of 
plasma standard calibration curves during a 
single day. Mean, standard deviation and 
coefficient of variation values were calculated 
for each concentration of the standard 
calibration curves. The accuracy of the 
estimates for each concentration was 
determined as the ratio of the mean 
concentration found after analysis to the 
nominal theoretical concentration, and 
expressed as a percentage. Inter-day 
precision and accuracy were evaluated for 18 
plasma standard calibration curves run on 3 
separate days (6 assays/day). This was 
expressed as coefficient of variation.  
Moreover, seeded control duplicate samples 
( 0.5, 1.5, 3.0) µg/ml were included in every 
analytical run of volunteers samples and 
injected just before and after each of these 
samples 
 
Stability study  
 
The stability of metronidazole in plasma was 
evaluated as short term stability or   bench 
top stability (for 6 hour at room temperature), 
long-term stability (6 weeks at -80 ºC) and 
freeze-thaw stability (Three  cycles). For thaw 
and freeze stability, replicates (n=6) of the 
low-QC and high-QC samples were analyzed 
after 3 freeze/thaw cycles. Samples were 
stored at approximately -80°C for at least 12 
hours between thaw cycles and thawed 
under ambient conditions and mixed gently. 
On the day of preparation and after the three 
freeze/thaw cycles the samples were 
analyzed against a standard curve and a 
blank. 
 
The acceptance criteria for the validated 
method were based on precision, accuracy, 
sensitivity, specificity and stability. An upper 
and lower limit of 10 % of the original 







Twenty four healthy adult male volunteers 
were included in this study. Their ages 
ranged from 21 to 43 years and their weight 
between 62 and 87 kg. On the basis of 
medical history, clinical examination and 
laboratory investigations (virus scanning, 
haematology, blood biochemistry and urine 
analysis), none of the participants revealed 
any medical abnormality. In addition, the 
subjects had no history of hospitalization or 
involvement in any clinical trials within the 
last 12 weeks. Informed written consent was 
obtained from the volunteers and the protocol 
of the study was approved by the Ethical 
Committee for Bioavailability Studies at 
National Organization for Drug Control and 
Research, Egypt. (approved no. 0509). The 
study was conducted in accordance with 
Good Clinical Practice guidelines and the 
Revised Declaration of Helsinki [12]. 
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Drug administration and blood sampling 
 
Each subject received the two products on 
two treatment days, separated by a two-week 
wash-out period. Each volunteer’s blood (5 
ml) was withdrawn via an indwelling cannula 
in the forearm at 0.0 (pre-dose), 0.25, 0.5, 
1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0  
and 24 hours. The cannula was kept clean of 
blood by flushing with heparinized saline after 
each sample collection. About 0.2 ml of blood 
was discarded from the cannula before each 
sample. The blood samples were transferred 
to the heparinized tubes and centrifuged for 5 
min at 3000 rpm. Plasma was separated with 
polypropylene disposable tips, transferred to 
Eppendorf  tubes and then stored in a 
laboratory deep freezer at -80 °C for 
sebsequent determination of metronidazole 
plasma levels as described above.  
 
Pharmacokinetic analysis  
 
Pharmacokinetic parameters of metronida-
zole were obtained using standard non-
compartmental methods. The maximal 
plasma concentration (Cmax) and the time to 
the peak plasma concentration (tmax) of 
metronidazole were derived directly from the 
data while the area under the plasma 
concentration-time curve (AUC) was 
calculated by the linear trapezoidal rule. The 
pharmacokinetic calculations were performed 
using the software, KineticaTM 2000 




All results were expressed as mean ± SD. 
Coefficient of variation (CV) for the obtained 
pharmacokinetic parameters as well as 
statistical analysis were performed by two-
way analysis of variance (ANOVA). AUC0-24, 
AUC0-∞ and Cmax values were logarithmically 
transformed prior to data analysis. On the 
other hand, the tmax values of the two 
preparations were analyzed using Wilcoxon 
Signed Rank Test for paired samples. For the 
parametric analysis of bioequivalence for log-
transformed data, the acceptance ranges 
were set at 80.0 -  125.0 % for both AUC0-t 
and Cmax. Statistical analysis was performed 





Selectivity and specificity  
 
The current method showed excellent 
chromatographic specificity with no 
endogenous plasma interference at the 
retention times of metronidazole and 
carbamazepine (IS). Metronidazole and 
carbamazepine were well resolved with 





The calibration curve was linear over the 
range of 0.05 – 30.0 µg/ml in human plasma. 
The regression coefficient of the curve, 
constructed from the mean standard curves 
analyzed in intra-day precision study (n = 3), 
was 0.999 and 0.998 for metronidazole 
dissolved in acetonitrile and that extracted 
from spiked plasma, respectively (Fig. 1). 
Low limit of detection (LLOQ) was 0.05 µg/ml 
and was at a signal to noise ratio of 5 times.  
 
Fig 1: Standard calibration curve (mean peak area 
vs. concentration in µg/ml) for metronidazole 
dissolved in mobile phase () and extracted from 
plasma (o)  
Table 1:  Intra-day and inter-day reproducibility of standard plasma calibration curve of metronidazole 
obtained by HPLC 
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Intra-day Inter-day  Theoretical conc. 
(µg/ml) Mean ± SD Accuracy (%) CV% Mean ± SD Accuracy (%) CV% 
0.05 0.053 ± 0.002 106.00 3.77 0.054 ± 0.005 108.00 9.26 
0.10 0.104 ± 0.001 104.00 0.96 0.104 ± 0.004 104.42 3.85 
0.50 0.532 ± 0.011 106.40 2.07 0.532 ± 0.014 106.15 2.63 
1.00 1.0193 ± 0.039 101.93 3.83 1.013 ± 0.031 101.28 3.60 
2.00 2.0085 ± 0.075 100.43 3.73 1.999 ± 0.078 99.96 3.90 
5.00 4.982 ± 0.237 99.64 4.76 4.997 ± 0.091 99.94 8.21 
10.00 9.951 ± 0.237 99.51 2.38 9.921 ± 0.165 99.22 1.66 
20.00 19.970 ± 0.40 99.85 2.00 20.110 ± 0.285 100.55 1.42 
30.00 29.947 ± 0.182 99.82 3.77 30.103 ± 0.239 100.34 0.79 
 
 
Table 2:  Peak area of  metronidazole dissolved in mobile phase and extracted from plasma 
 
* Metronidazole dissolved in mobile phase injected directly; * *Metronidazole spiked in plasma injected after 
liquid-liquid extraction;    *** Absolute Recovery = 89.6 
 
 
The mean of coefficient of variation (CV%) 
data are presented in Table 1. 
 
Accuracy, precision, recovery and quality 
control 
 
The assay showed good intra-day and inter-
day precision, and accuracy over the entire 
calibration range. The precision of the 
developed method (CV %) varied from 0.96 
to 4.76 % and from 0.79 to 9.26 % for intra-
assay and inter-assay respectively. The 
mean accuracy of the developed method 
ranged between 99.51 to 106.40% for intra-
assay and from 99.22 to 108.00% inter-
assay, (Table 1). The absolute recovery of 
metronidazole was 89.6 % (Table 2). The 
variation between runs (CV %) for the quality 
control samples was < 10 %. 
The mean plasma drug concentration vs. 
time curves following oral administration of 
metronidazole suspension are presented in 
Figure 2 and Table 3. Maximum plasma 
concentrations of metronidazole was 9.64 ± 
2.61 µg/ml and 8.38 ± 2.52 µg/ml for test and 
reference products, respectively, while the 
time to reach these maximum concentrations 
was about 2.75 and 3.0 h, respectively. Total 
area under the curve (AUC0-∞) was 140.9 ± 
50.7 and 128.4 ± 29.7 µg.h/ml for test and 
reference tablets, respectively, while mean 
residence time  was 16.3 ± 7.6 and 14.1 ± 2.7 
h, respectively. Half-life (t1/2) was 12.45 ± 
5.36 and 10.89 ± 1.95 for test and reference  
Table 3:  Pharmacokinetic parameters of metronidazole in healthy volunteers 
 
Parameter Test Reference 90% CI 
Mobile phase * Plasma ** Conc. 
(µg/ml) Mean SD CV% Mean SD CV% 
Recovery  
(%) *** 
0.05 8386.17 404.78 4.827 6308.33 525.04 8.323 75.223 
0.1 13001.67 434.83 3.344 9422.47 915.53 9.716 72.471 
0.50 62761.83 1429.22 2.277 55310.3 1716.25 3.103 88.127 
1.00 127121.33 4155.65 3.269 115341 6329.06 5.487 90.733 
2.00 238267.17 7843.43 3.292 224694 11827.4 5.264 94.304 
5.00 586335.50 24933.06 4.252 602883 44043.2 7.305 102.822 
10.00 1210552.00 56451.08 4.663 1207019 106465 8.821 99.708 
20.00 2429618.00 95142.00 3.916 2205425 204503 9.278 90.773 
30.00 3556699.83 38368.06 1.079 3278891 308711 9.415 92.189 
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Mean Range Mean Range 
Cmax (µg/ml) 9.64 ± 2.61 5.77 -19.09 8.38 ± 2.52 4.22 - 12.94 0.927 – 1.100 
tmax (h) 2.75 ± 1.06 2.00 - 6.00 3.00  ± 1.17 2.0 - 8.0  _ 
AUC0-24 (µg.h/ml) 124.6 ± 32.35 59.5 – 186.6 122.3 ± 28.8 78.2 – 179.5 0.973 – 1.051 
AUC0-inf (µg.h/ml) 140.9 ± 50.67 82.0 – 300.7 128.4 ± 29.65 79.6 – 189.0 1.147 – 1.233 
t1/2 (h) 12.45 ± 5.36 6.74 – 30.56 10.89 ± 1.95 6.64 – 14.68 1.234 – 1.425 
MRT (h) 16.33 ± 7.64 9.99 – 44.37 14.05 ± 2.68 8.31 – 17.83 0.429 – 1.036 
 
products, respectively. There was no 
significant difference between the test and 
reference products in respect of the 
pharmacokinetic parameters required for 
assessment of drug bioequivalence (Cmax, 
AUC and tmax), and this was within the 
bioequivalence acceptance range of 0.80 - 
1.25 for log transformed data. 
 
Fig 2: Plasma concentration of metronidazole 
following administration of test metronidazole 





A simple, sensitive, cost-effective, and 
reliable HPLC method for determination of 
metronidazole in human plasma over the 
concentration range 0.05–30 μg/mL has been 
developed and validated. Several methods 
for the determination of metronidazole in 
biological fluids has previously been 
published. Some of these methods required 
the use of relatively large volume of plasma 
or extraction solvent [7,8]. Other more 
complicated extraction procedures, such as 
solid-phase extraction, have also been 
reported [5,13]. Solid-phase extraction 
procedures require solid-phase extraction 
cartridges, which increase the cost of the 
analysis. Some recent studies reported the 
determination of metronidazole by LC-MS-
MS detection (4,6] but this method is not 
economical for routine use in pharmaco-
kinetic studies since numerous samples must 
be analysed.  
 
The method applied here was accurate, 
precise, specific, sensitive and capable of 
determining concentrations of metronidazole 
in a small volume of human plasma (200 µl) 
and entails reduced utilization of organic 
solvent. This assay method was also rapid 
(one step only), and the preparation of 96 
samples took less than 90 min from the initial 
extraction step to final placement of samples 
in the HPLC auto-sampler vials. Morover, the 
protein precipitation was carried out using 
methanol rather than the perchloric acid  
used in another method [8]; perchloric acid 
an affect the life span of the separation 




We can conclude that metronidazole 125 
mg/5 ml suspension (Brand A) is 
bioequivalent to the commercial standard, 
Flagyl® 125mg/5ml suspension (Aventis 
Pharma). The present method was useful for 
the determination of the bioequivalence of 
metronidazole products, and would,also be 
useful for routine drug monitoring and other 
bioavailability studies with the desired 
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